DoubleVerify projects that Social and CTV products will drive approximately 32-39% of total revenue in 2026, underpinning its 8-10% full-year revenue growth guidance. The 2026 midpoint revenue guide reflects significant growth fueled by expanding adoption and scaling of these product lines.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
Can you quantify assumed revenue contribution from Social and CTV products in the 2026 midpoint guide?
Analysis of Assumed Revenue Contribution from Social and CTV Products in DoubleVerify’s 2026 Midpoint Revenue Guidance
2026 Revenue Guidance Overview
DoubleVerify (DV) provided full year 2026 revenue guidance of $810 million to $826 million, which implies expected year-over-year revenue growth of 8% to 10% over 2025’s revenue of $748 million 12. The midpoint of this range is approximately $818 million.
Growth Drivers Highlighted by Management
Management explicitly identifies three key product-led growth engines supporting the 2026 revenue outlook:
The revenue guidance assumes a measured view on the impact of these Social and CTV products’ scaling during 2026 and does not assume a macro advertising environment improvement 2.
Social Revenue Growth Trends and Scale
CTV Revenue Growth and Scaling Dynamics
Quantitative Contribution Estimation
Although the company does not disclose an exact dollar figure or percentage explicitly allocated to Social and CTV revenues in the 2026 midpoint guidance, we can infer from existing data and growth rates:
Using 2025 revenue of $748 million, 30% is approximately $224 million attributed to Social, CTV, and AI combined. If we conservatively allocate Social and CTV together to about 25-27% (with AI taking the balance ~3-5%), Social and CTV contributed roughly $187 to $202 million in 2025 revenue.
For 2026 guidance midpoint of $818 million, an 8.5% increase over 2025, if Social and CTV grow materially faster than the core business (60% growth in Social activation in Q4 2025 trending upward, double-digit growth anticipated in CTV), their revenue in 2026 could be estimated to grow by 40-60%, possibly increasing to around $260 to $320 million. This implies roughly 32-39% of the 2026 midpoint revenue may come from Social and CTV products.
Management’s Measured Approach in Growth Assumptions
The company’s commentary reflects a measured stance on growth from these product lines in 2026, meaning management is not assuming hyper-growth but rather steady scaling as adoption deepens:
Summary
In conclusion, based on the detailed management commentary and reported product mix, the assumed revenue contribution from Social and CTV products embedded in the 2026 midpoint guide of $818 million is likely in the range of $260 million to $320 million, representing roughly one-third to two-fifths of total projected revenue and a key engine driving overall revenue growth in 2026.
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
🚀 DoubleVerify explores the rising frontier of advertising within AI-driven LLM platforms in its Q2 2025 earnings, signaling strategic readiness for future ad verification opportunities. 🤖📊
Sources used
Research questionLLM
Answer outline
Marvell attributes near-term data center margin pressure to the expanding mix of custom silicon, with management emphasizing that revenue levels and product mix drive gross margins each quarter. While the Q3 headwind is primarily a mix effect, management expects margins to stabilize as the custom ramp accelerates in H2 and broad-based growth supports margin expansion into fiscal 2028.
Sources used
Research questionWhat did management say about Data center margin drivers from custom mix?
Answer outline
Investors should read management’s “2H acceleration” as a qualitative uptick in the second half versus the first half, supported by guidance for sequential back-half growth and a Helios ramp that becomes more impactful in Q4. The Q2 107% YoY growth establishes the first-half baseline, with Q3 and Q4 expected to exceed it through supply and product timing.
Sources used
Research questionHow should investors interpret management’s view that data center AI growth will “accelerate” in the second half versus the first half, given Q2’s 107% year-over-year growth and the Q3/Q4 guidance trajectory?
Answer outline
Western Digital outlines a dual-path outlook: LTA pricing remains contract-driven and predictable, particularly for nearline pricing, while offering upside in non-nearline contracts, and the exabyte growth trajectory remains robust at 25% plus, supported by 40TB ePMR ramp and upcoming HAMR and higher-capacity drives, with visibility extending through 2029–2031. Quarterly margins may vary due to LTA timing, but the long-term demand signal remains strong.
Sources used
Research questionWhat did management say about LTA pricing and exabyte growth outlook?
Answer outline
Pfizer's update highlights a $1.5 billion year-to-date non-COVID uplift driven by Eliquis alongside other products like NURTEC and Padcev, though the exact split isn’t quantified. Eliquis is projected to grow 20%–25% this year, while Padcev shows an initial acceleration that should moderate as la/mUC penetration matures, with upside potential from MIBC over time.
Sources used
Research questionWithin the $1.5 billion year-to-date increase in non-COVID revenue guidance, how much is due to Eliquis versus other products, and what is the updated Eliquis growth outlook? Also, with Padcev's expanded label, what is the expected growth path for that asset going forward?
Answer outline
Match Group's Q2 2026 earnings discussion centers on a consistent MAU-payer trend correlation, where payer declines run smaller than MAU declines and payer penetration rose year over year. Management notes MAU momentum drives direct revenue per MAU and payer trends over time, but warns quarterly movements can diverge due to product and monetization initiatives, while maintaining a positive long-term outlook and guidance for payer declines to ease in H2.
Sources used
Research questionWhat did management say about MAU and payer trend correlation?
Answer outline
IFF's Scent segment posted an 8% Q2 sales rise led by double-digit growth in Fragrance Ingredients and a resilient Consumer Fragrance line, even as Fine Fragrance faced Middle East volatility. The firm outlines a two-track H2: mid-single-digit growth for Fine Fragrance with a Q3 soft patch and a rebound in Q4, while Consumer Fragrance normalizes after a standout Q2, underpinned by an R&D-driven push into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is advancing on multiple fronts, led by volume-driven growth, a re-energized R&D pipeline, and stable management of regional volatility. In 2H, Fine Fragrance should soften in Q3 and rebound in Q4, while Consumer Fragrance normalizes to a low single-digit pace, with 2027 R&D investments positioned to bolster long-term competitive strength.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Management ties the Scent recovery to a significantly stronger R&D pipeline and execution, with Scent sales up 8% and EBITDA up 5% driven by volume gains and productivity. For 2H, Fine Fragrance is expected to be soft in Q3 but stronger in Q4, while Consumer Fragrance should normalize to low-single-digit growth; the 2027 plan emphasizes sustained R&D investment, perfumer-led innovation, and a shift toward higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is led by Fragrance Ingredients and volume gains, with Fine Fragrance expected to be softer in Q3 and rebound in Q4. The company emphasizes a rebuilt R&D pipeline and higher-value product shifts to support competitive positioning into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery driven by a strengthened R&D pipeline, improved go-to-market execution, and a strategy to lift market share across Fine and Consumer Fragrance. The company anticipates a softer Q3 but a stronger Q4 for Fine Fragrance and a normalization to low single-digit growth for Consumer Fragrance in H2, supported by an 8-9% of sales R&D investment through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF Scent’s recovery hinges on a rebuilt R&D engine and market-share gains in Consumer Fragrance, with Fine Fragrance stabilizing amid Middle East volatility and Fragrance Ingredients normalization. In H2, Fine Fragrance is expected to soften in Q3 and strengthen in Q4, while Consumer Fragrance normalizes to low single-digit growth; management also emphasizes sustaining R&D investment around 8-9% of sales to support 2027 competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi